That Escalated Quickly: Remdesivir's Place in Therapy for COVID-19

Remdesivir is a nucleoside antiviral recently studied in several randomized trials for treatment of COVID-19. The available observational and prospective data are conflicting, requiring clinicians to critically evaluate and reconcile results to determine patient populations that may optimally benefi...

Descripción completa

Detalles Bibliográficos
Autores principales: Davis, Matthew R., McCreary, Erin K., Pogue, Jason M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7348566/
https://www.ncbi.nlm.nih.gov/pubmed/32651941
http://dx.doi.org/10.1007/s40121-020-00318-1
_version_ 1783556858369277952
author Davis, Matthew R.
McCreary, Erin K.
Pogue, Jason M.
author_facet Davis, Matthew R.
McCreary, Erin K.
Pogue, Jason M.
author_sort Davis, Matthew R.
collection PubMed
description Remdesivir is a nucleoside antiviral recently studied in several randomized trials for treatment of COVID-19. The available observational and prospective data are conflicting, requiring clinicians to critically evaluate and reconcile results to determine patient populations that may optimally benefit from remdesivir therapy, especially while drug supply is scarce. In this review, we analyze pertinent clinical remdesivir data for patients with COVID-19 from January 1, 2020, through May 31, 2020.
format Online
Article
Text
id pubmed-7348566
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Springer Healthcare
record_format MEDLINE/PubMed
spelling pubmed-73485662020-07-10 That Escalated Quickly: Remdesivir's Place in Therapy for COVID-19 Davis, Matthew R. McCreary, Erin K. Pogue, Jason M. Infect Dis Ther Review Remdesivir is a nucleoside antiviral recently studied in several randomized trials for treatment of COVID-19. The available observational and prospective data are conflicting, requiring clinicians to critically evaluate and reconcile results to determine patient populations that may optimally benefit from remdesivir therapy, especially while drug supply is scarce. In this review, we analyze pertinent clinical remdesivir data for patients with COVID-19 from January 1, 2020, through May 31, 2020. Springer Healthcare 2020-07-10 2020-09 /pmc/articles/PMC7348566/ /pubmed/32651941 http://dx.doi.org/10.1007/s40121-020-00318-1 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.
spellingShingle Review
Davis, Matthew R.
McCreary, Erin K.
Pogue, Jason M.
That Escalated Quickly: Remdesivir's Place in Therapy for COVID-19
title That Escalated Quickly: Remdesivir's Place in Therapy for COVID-19
title_full That Escalated Quickly: Remdesivir's Place in Therapy for COVID-19
title_fullStr That Escalated Quickly: Remdesivir's Place in Therapy for COVID-19
title_full_unstemmed That Escalated Quickly: Remdesivir's Place in Therapy for COVID-19
title_short That Escalated Quickly: Remdesivir's Place in Therapy for COVID-19
title_sort that escalated quickly: remdesivir's place in therapy for covid-19
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7348566/
https://www.ncbi.nlm.nih.gov/pubmed/32651941
http://dx.doi.org/10.1007/s40121-020-00318-1
work_keys_str_mv AT davismatthewr thatescalatedquicklyremdesivirsplaceintherapyforcovid19
AT mccrearyerink thatescalatedquicklyremdesivirsplaceintherapyforcovid19
AT poguejasonm thatescalatedquicklyremdesivirsplaceintherapyforcovid19

Ejemplares similares